Kura Oncology Inc (KURA) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising Expenses
There may be an opportunity to use MRD negativity as a surrogate endpoint in an accelerated design, but it's not yet approved by health...authorities. We ...
GuruFocus.com via Yahoo
5 days ago
